

**DOMINICK LATRÉMOUILLE-VIAU**  
**Vice President**

Direct: 514 394 4431  
dominick.latremouille-viau@analysisgroup.com

1190 avenue des Canadiens-de-Montréal  
Tour Deloitte, Suite 1500  
Montreal, Quebec H3B 0G7

Ms. Latrémouille-Viau is an economist who specializes in health economics and outcomes research (HEOR) and epidemiology. She has extensive experience in designing chart review and survey studies, as well as in analyzing outcomes associated with a range of pharmaceuticals and medical devices using medical claims data and electronic health records. Ms. Latrémouille-Viau has participated in the design of real-world evidence (RWE) studies to support regulatory submissions and the development of HEOR planning and RWE generation plans. She has worked with large health care firms to conduct studies investigating safety, efficacy, treatment patterns, comorbidity profiles, disease prevalence and incidence, patient-reported outcomes (PROs), discrete choice experiments, resource utilization, direct medical costs, and indirect productivity costs. Her research has covered many therapeutic areas, including autoimmune diseases, solid tumors, blood cancer, cardiology and circulatory diseases, and respiratory diseases. Ms. Latrémouille-Viau has published research papers in numerous peer-reviewed journals and presented studies at various scientific conferences.

**EDUCATION**

2007            M.Sc., economics, University of Québec at Montréal  
2004            B.Sc., economics, University of Québec at Montréal

**PROFESSIONAL EXPERIENCE**

2006–Present    Analysis Group, Inc.  
                         *Vice President (2023–Present)*  
                         *Manager (2013–2022)*  
                         *Associate (2006–2012)*

**ARTICLES AND PUBLICATIONS**

Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States. Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P. *Medicine (Baltimore)*. 2023 Mar 24;102(12):e33072.

Healthcare Resource Utilization and Costs Among Patients with Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States. Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P. *J Health Econ Outcomes Res*. 2023 Mar 3;10(1):51-58.

Real-world experience of pediatric patients treated with peanut (*Arachis hypogaea*) allergen powder-dnfp. Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latrémouille-Viau D, Bungay R, Chen K, McCann W. *Ann Allergy Asthma Immunol*. 2023 Feb 2:S1081-1206(23)00079-0.

Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. Atallah EL, Maegawa R, Latrémouille-Viau D, Rossi C, Guérin A. *J Health Econ Outcomes Res.* 2022 Aug 4;9(2):30-36.

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. Atallah EL, Maegawa R, Latrémouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. *J Health Econ Outcomes Res.* 2022 Aug 4;9(2):19-29.

Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individuals. Meadows JA, Yu S, Hass SL, Guérin A, Latrémouille-Viau D, Tilles SA. *Allergy Asthma Proc.* 2021 Jul 1;42(4):333-342.

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V. *Leuk Lymphoma.* 2021 Jul;62(7):1730-1739.

Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. *J Med Econ.* 2021 Jan-Dec;24(1):234-243.

Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States. Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guérin A, Latrémouille-Viau D, Tilles SA. *J Manag Care Spec Pharm.* 2021 Apr;27(4):516-527.

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. *Leuk Lymphoma.* 2021 Jun;62(6):1411-1421.

Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers. Shah NR, Bhor M, Latrémouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guérin A. *J Med Econ.* 2020 Nov;23(11):1345-1355.

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Ritchie EK, Latrémouille-Viau D, Guérin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL. *Leuk Lymphoma.* 2019 Jun;60(6):1476-1484.

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review. Joshi R, Latrémouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P. *Drugs Real World Outcomes.* 2019 Mar;6(1):1-9.

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review. Sunkureddi P, Latrémouille-Viau D, Meiselbach MK, Xie J, Hur P, Joshi R. *Rheumatol Ther.* 2019 Mar;6(1):89-100.

Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ. *Adv Ther.* 2018 Oct;35(10):1671-1685.

Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. Stein EM, Bonifacio G, Latrémouille-Viau D, Guérin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ. *J Med Econ.* 2018 Jun;21(6):556-563.

Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Latrémouille-Viau D, Guérin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. *J Manag Care Spec Pharm*. 2017 Feb;23(2):214-224.

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. Latrémouille-Viau D, Guérin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. *J Med Econ*. 2017 Jan;20(1):63-71.

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States. Latrémouille-Viau D, Chang J, Guérin A, Shi S, Wang E, Yu J, Ngai C. *J Med Econ*. 2017 Jan;20(1):54-62.

Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Smith BD, Liu J, Latrémouille-Viau D, Guérin A, Fernandez D, Chen L. *Curr Med Res Opin*. 2016 May;32(5):817-27.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Langer C, Ravelo A, Hazard SJ, Guérin A, Ionescu-Ittu R, Latrémouille-Viau D, Wu EQ, Ramalingam S. *Lung Cancer*. 2014 Dec;86(3):350-7.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Hurvitz S, Guérin A, Brammer M, Guardino E, Zhou ZY, Latrémouille-Viau D, Wu EQ, Lalla D. *Oncologist*. 2014 Sep;19(9):901-8.

Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. Bron M, Guérin A, Latrémouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ. *J Med Econ*. 2014 Sep;17(9):646-57

A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latrémouille-Viau D, Wu EQ, Shi L. *Pediatr Pulmonol*. 2013 Oct;48(10):954-61.

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS, Signorovitch JE, Zhang J, Latrémouille-Viau D, von Wartburg M, Wu EQ, Shi L. *Pediatr Pulmonol*. 2012 Jan;47(1):44-52.

Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Wu EQ, Forsythe A, Guérin A, Yu AP, Latrémouille-Viau D, Tsaneva M. *Am J Ther*. 2012 Nov;19(6):e157-66.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latrémouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE. *Pain Med*. 2010 Nov;11(11):1718-25.

Economic burden associated with the use of generic antiepileptic drugs in the United States. Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Labiner DM. *Epilepsy Behav*. 2010 Aug;18(4):437-44.

Generic antiepileptic drugs and associated medical resource utilization in the United States. Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Helmers SL. *Neurology*. 2010 May 18;74(20):1566-74.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Kimball AB, Guérin A, Latrémouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P. *Am J Med.* 2010 Apr;123(4):350-7.

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Signorovitch J, Zhang J, Wu EQ, Latrémouille-Viau D, Yu AP, Dastani HB, Kahler KH. *Curr Med Res Opin.* 2010 Apr;26(4):849-60.

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Saurat JH, Guérin A, Yu AP, Latrémouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. *Dermatology.* 2010;220(2):128-37.

The risks and costs of multiple-generic substitution of topiramate. Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J. *Neurology.* 2009 Jun 16;72(24):2122-9.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS. *Curr Med Res Opin.* 2009 Jul;25(7):1793-805.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. Lichtenberg FR, Grootendorst P, Van Audenrode M, Latrémouille-Viau D, Lefebvre P. *Value Health.* 2009 Sep;12(6):847-56.

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Parfrey PS, Lauve M, Latrémouille-Viau D, Lefebvre P. *Clin J Am Soc Nephrol.* 2009 Apr;4(4):755-62.

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O. *Curr Med Res Opin.* 2008 Apr;24(4):1069-81.

## **LANGUAGES**

French (native)